Cantor Fitzgerald Reiterates Overweight on Mind Medicine

Cantor Fitzgerald analyst Charles Duncan reiterates Mind Medicine (NASDAQ:MNMD) with a Overweight.

BenzingaJun 22 00:31

MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of

BusinesswireJun 21 19:00

MindMed Announces Constructive End-of-Phase 2 Meeting With U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

-Aligned on requirements for Phase 3 clinical development of MM120 for the treatment of GAD- -Initiation of Phase 3 program remains on schedule to begin in second half of 2024- Mind Medicine (MindMed) Inc.

BusinesswireJun 20 19:00

Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?

Yahoo FinanceJun 14 21:40

Leerink Partners Maintains Mind Medicine(MNMD.US) With Buy Rating

Leerink Partners analyst Rudy Li maintains $Mind Medicine(MNMD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 36.8% and a total average return of 11.2% over the p

Futu NewsJun 12 15:31 · Ratings

Baird Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $27

Baird analyst Joel Beatty maintains $Mind Medicine(MNMD.US)$ with a buy rating, and maintains the target price at $27.According to TipRanks data, the analyst has a success rate of 46.7% and a total av

Futu NewsJun 6 15:32